Actuate Therapeutics Inc (ACTU)

$2.56 +0.01 (0.39%)
Market Cap 59.50M
Revenue (ttm) 0.00
Net Income (ttm) -27.29M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 120,700
Avg Vol 70,604
Day's Range N/A - N/A
Shares Out 23.24M
Stochastic %K 16%
Beta 0.10
Analysts Strong Sell
Price Target $25.00

Company Profile

Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancers in the United States. The company's lead product candidate is elraglusib injection, a glycogen synthase kinase-3 inhibitor that is in Phase 2 trial to treat metastatic pancreatic ductal adenocarcinoma. It also develops elraglusib, which is in Phase 1/2 trial for the treatment of refractory pediatric malignancies, including Ewing sarcoma, as well as metastatic melanoma and color...

Industry: Biotechnology
Sector: Healthcare
Phone: 817 887 8455
Address:
1751 River Run, Suite 400, Fort Worth, United States
rombrento
rombrento Mar. 13 at 3:29 AM
$ACTU
0 · Reply
StockNews_Live
StockNews_Live Mar. 9 at 12:45 PM
$ACTU 💵 Price: $2.89 (-10.63%) 🔥 Sentiment Score: 85/100 🚀 VERY POSITIVE NEWS 📄 Actuate Therapeutics, Inc. announced the launch of an expanded research initiative evaluating combinations of its clinical-stage GSK-3β inhibitor elraglusib with emerging RAS-targeted therapies. The… 📎 https://stocknews.live/news/ACTU/actuate-therapeutics-launches-strategic-69364.html
0 · Reply
focafoca99
focafoca99 Mar. 4 at 11:50 PM
$ACTU presenting at Citizens Life Sciences keeps it in front of healthcare investors
0 · Reply
TimmyTheSleuth
TimmyTheSleuth Mar. 4 at 3:28 PM
$ACTU who’s in this?
0 · Reply
VentureDebtView
VentureDebtView Feb. 20 at 1:10 PM
$ACTU Actuate Therapeutics is an early-stage oncology biotech. Valuation depends entirely on clinical progress. Funding risk remains elevated.
0 · Reply
BillionerOfKing
BillionerOfKing Feb. 18 at 12:28 PM
$ACTU Current Stock Price: $4.30
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 18 at 10:01 AM
$ACTU RSI: 23.79, MACD: -0.4610 Vol: 0.53, MA20: 4.82, MA50: 5.86 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
chartWizards
chartWizards Feb. 15 at 5:45 AM
$ACTU Early-stage biotech with elraglusib in clinical trials; analyst targets imply >200% upside but depend on successful data.
0 · Reply
FloatFlare
FloatFlare Feb. 10 at 1:09 PM
$ACTU is a software or technology company; must prove sustainable growth and competitive advantage.
0 · Reply
BioTuesdays
BioTuesdays Jan. 21 at 7:22 PM
$ACTU has announced plans to initiate a Phase 1/2 clinical program evaluating the oral tablet dosage form of elraglusib in patients with advanced cancer https://biotuesdays.com/2026/01/21/actuate-to-advance-elraglusib-tablet-to-phase-1-2-program-in-refractory-cancers/
0 · Reply
Latest News on ACTU
Actuate Therapeutics Launches Strategic Research Initiative to Combine Elraglusib with RAS Inhibitors

Mar 9, 2026, 8:45 AM EDT - 6 days ago

Actuate Therapeutics Launches Strategic Research Initiative to Combine Elraglusib with RAS Inhibitors

Actuate Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

Feb 24, 2026, 8:45 AM EST - 19 days ago

Actuate Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

Actuate Therapeutics Reports Positive Follow-Up Data from its Randomized Controlled Phase 2 Trial Demonstrating Extended Long-Term Overall Survival Benefit with Elraglusib Plus Chemotherapy for Metastatic Pancreatic Cancer in Oral Presentation at ASCO GI 2026

Jan 12, 2026, 8:45 AM EST - 2 months ago

Actuate Therapeutics Reports Positive Follow-Up Data from its Randomized Controlled Phase 2 Trial Demonstrating Extended Long-Term Overall Survival Benefit with Elraglusib Plus Chemotherapy for Metastatic Pancreatic Cancer in Oral Presentation at ASCO GI 2026

Actuate Therapeutics Announces Positive Patient Outcomes from Phase 1 Trial in Difficult-to-Treat Refractory Pediatric Cancers

Jan 6, 2026, 8:45 AM EST - 2 months ago

Actuate Therapeutics Announces Positive Patient Outcomes from Phase 1 Trial in Difficult-to-Treat Refractory Pediatric Cancers

Actuate Therapeutics Phase 2 Metastatic Pancreatic Cancer Data Selected for Oral and Poster Presentation at ASCO GI 2026

Dec 18, 2025, 8:45 AM EST - 3 months ago

Actuate Therapeutics Phase 2 Metastatic Pancreatic Cancer Data Selected for Oral and Poster Presentation at ASCO GI 2026

Actuate Therapeutics Provides FDA with Updated Clinical Data Package to Support Planned Regulatory Interactions with FDA and EMA Over the Coming Months

Sep 22, 2025, 8:45 AM EDT - 6 months ago

Actuate Therapeutics Provides FDA with Updated Clinical Data Package to Support Planned Regulatory Interactions with FDA and EMA Over the Coming Months

Actuate Therapeutics Announces Pricing of $15.0 Million Public Offering of Common Stock

Sep 10, 2025, 8:31 AM EDT - 6 months ago

Actuate Therapeutics Announces Pricing of $15.0 Million Public Offering of Common Stock

Actuate Therapeutics Announces Proposed Public Offering of Common Stock

Sep 9, 2025, 4:07 PM EDT - 6 months ago

Actuate Therapeutics Announces Proposed Public Offering of Common Stock

Actuate Therapeutics To Collaborate with Incyte Corporation and the University of Pittsburgh on Clinical Trial of Elraglusib in Combination with Retifanlimab and mFOLFIRINOX in Patients with Advanced Pancreatic Cancer

Aug 6, 2025, 8:45 AM EDT - 7 months ago

Actuate Therapeutics To Collaborate with Incyte Corporation and the University of Pittsburgh on Clinical Trial of Elraglusib in Combination with Retifanlimab and mFOLFIRINOX in Patients with Advanced Pancreatic Cancer

Actuate Therapeutics Advances Clinical Program in Ewing Sarcoma After Positive Phase 1 Trial Demonstrates Complete and Partial Responses in Difficult-to-Treat Pediatric Sarcomas

Jul 17, 2025, 8:45 AM EDT - 8 months ago

Actuate Therapeutics Advances Clinical Program in Ewing Sarcoma After Positive Phase 1 Trial Demonstrates Complete and Partial Responses in Difficult-to-Treat Pediatric Sarcomas

Actuate Therapeutics Highlights Significant and Sustained Survival Benefit in Key Metastatic Pancreatic Cancer Patient Populations in Phase 2 Elraglusib Trial

Jun 24, 2025, 9:15 AM EDT - 9 months ago

Actuate Therapeutics Highlights Significant and Sustained Survival Benefit in Key Metastatic Pancreatic Cancer Patient Populations in Phase 2 Elraglusib Trial

Actuate Therapeutics Reports Positive Biomarker and Machine Learning Data from Phase 2 Elraglusib Trial in First-Line Treatment of Metastatic Pancreatic Cancer at ASCO

Jun 20, 2025, 8:45 AM EDT - 9 months ago

Actuate Therapeutics Reports Positive Biomarker and Machine Learning Data from Phase 2 Elraglusib Trial in First-Line Treatment of Metastatic Pancreatic Cancer at ASCO

Actuate Therapeutics Announces Inclusion in the Russell 3000® and Russell 2000® Indexes

Jun 16, 2025, 8:30 AM EDT - 9 months ago

Actuate Therapeutics Announces Inclusion in the Russell 3000® and Russell 2000® Indexes

Actuate Therapeutics Presents Topline Elraglusib Phase 2 Data at ASCO 2025 Annual Meeting: Trial Meets Primary Endpoint of Median Overall Survival and Doubles 1-Year Survival in First-Line Treatment of Metastatic Pancreatic Cancer

May 31, 2025, 4:30 PM EDT - 10 months ago

Actuate Therapeutics Presents Topline Elraglusib Phase 2 Data at ASCO 2025 Annual Meeting: Trial Meets Primary Endpoint of Median Overall Survival and Doubles 1-Year Survival in First-Line Treatment of Metastatic Pancreatic Cancer

Actuate Therapeutics Announces Details for 2025 ASCO Annual Meeting Presentation on Topline Elraglusib Phase 2 Data in First-Line Treatment of Metastatic Pancreatic Cancer

May 22, 2025, 5:05 PM EDT - 10 months ago

Actuate Therapeutics Announces Details for 2025 ASCO Annual Meeting Presentation on Topline Elraglusib Phase 2 Data in First-Line Treatment of Metastatic Pancreatic Cancer

Actuate to Present Elraglusib Phase 2 Topline Data at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Apr 23, 2025, 10:24 AM EDT - 11 months ago

Actuate to Present Elraglusib Phase 2 Topline Data at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Actuate to Present Promising Data on Elraglusib in Advanced Salivary Gland Carcinoma at the AACR Annual Meeting 2025

Apr 17, 2025, 8:00 AM EDT - 11 months ago

Actuate to Present Promising Data on Elraglusib in Advanced Salivary Gland Carcinoma at the AACR Annual Meeting 2025

Actuate Therapeutics to Participate in Upcoming Investor Conferences in February

Feb 6, 2025, 8:00 AM EST - 1 year ago

Actuate Therapeutics to Participate in Upcoming Investor Conferences in February

Actuate Therapeutics Announces Positive Interim Phase 2 Data of Elraglusib in First Line Treatment of Metastatic Pancreatic Cancer

Dec 17, 2024, 8:28 AM EST - 1 year ago

Actuate Therapeutics Announces Positive Interim Phase 2 Data of Elraglusib in First Line Treatment of Metastatic Pancreatic Cancer

Actuate to Participate in Lantern's Pharma Webinar on AI-Driven Drug Development

Oct 29, 2024, 6:39 PM EDT - 1 year ago

Actuate to Participate in Lantern's Pharma Webinar on AI-Driven Drug Development

Actuate Therapeutics Obtains Complete Responses and Provides Update on Clinical Trial of Elraglusib for the Treatment of Relapsed/Refractory Ewing Sarcoma

Sep 9, 2024, 8:00 AM EDT - 1 year ago

Actuate Therapeutics Obtains Complete Responses and Provides Update on Clinical Trial of Elraglusib for the Treatment of Relapsed/Refractory Ewing Sarcoma

Actuate to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Sep 5, 2024, 9:10 AM EDT - 1 year ago

Actuate to Present at the H.C. Wainwright 26th Annual Global Investment Conference

U.S. IPO Weekly Recap: WeRide Reschedules While 6 New Filers Join The Pipeline

Aug 17, 2024, 5:10 AM EDT - 1 year ago

U.S. IPO Weekly Recap: WeRide Reschedules While 6 New Filers Join The Pipeline

HCAI TDTH WRD YXT

Actuate Therapeutics Announces Closing of Initial Public Offering

Aug 14, 2024, 4:05 PM EDT - 1 year ago

Actuate Therapeutics Announces Closing of Initial Public Offering

Actuate Therapeutics Announces Pricing of Initial Public Offering

Aug 12, 2024, 8:27 PM EDT - 1 year ago

Actuate Therapeutics Announces Pricing of Initial Public Offering

U.S. IPO Weekly Recap: August Kicks Off With One Small Pricing

Aug 3, 2024, 12:30 AM EDT - 1 year ago

U.S. IPO Weekly Recap: August Kicks Off With One Small Pricing

GFL OSTX

U.S. IPO Weekly Recap: Insurance And Healthcare Lead A 4 IPO Week

Jul 20, 2024, 4:50 AM EDT - 1 year ago

U.S. IPO Weekly Recap: Insurance And Healthcare Lead A 4 IPO Week

ARDT ARTV CON LINE OS QMMM TWFG

Actuate Therapeutics Seeks IPO For Promising Pancreatic Cancer Drugs

May 28, 2024, 5:34 PM EDT - 1 year ago

Actuate Therapeutics Seeks IPO For Promising Pancreatic Cancer Drugs

rombrento
rombrento Mar. 13 at 3:29 AM
$ACTU
0 · Reply
StockNews_Live
StockNews_Live Mar. 9 at 12:45 PM
$ACTU 💵 Price: $2.89 (-10.63%) 🔥 Sentiment Score: 85/100 🚀 VERY POSITIVE NEWS 📄 Actuate Therapeutics, Inc. announced the launch of an expanded research initiative evaluating combinations of its clinical-stage GSK-3β inhibitor elraglusib with emerging RAS-targeted therapies. The… 📎 https://stocknews.live/news/ACTU/actuate-therapeutics-launches-strategic-69364.html
0 · Reply
focafoca99
focafoca99 Mar. 4 at 11:50 PM
$ACTU presenting at Citizens Life Sciences keeps it in front of healthcare investors
0 · Reply
TimmyTheSleuth
TimmyTheSleuth Mar. 4 at 3:28 PM
$ACTU who’s in this?
0 · Reply
VentureDebtView
VentureDebtView Feb. 20 at 1:10 PM
$ACTU Actuate Therapeutics is an early-stage oncology biotech. Valuation depends entirely on clinical progress. Funding risk remains elevated.
0 · Reply
BillionerOfKing
BillionerOfKing Feb. 18 at 12:28 PM
$ACTU Current Stock Price: $4.30
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 18 at 10:01 AM
$ACTU RSI: 23.79, MACD: -0.4610 Vol: 0.53, MA20: 4.82, MA50: 5.86 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
chartWizards
chartWizards Feb. 15 at 5:45 AM
$ACTU Early-stage biotech with elraglusib in clinical trials; analyst targets imply >200% upside but depend on successful data.
0 · Reply
FloatFlare
FloatFlare Feb. 10 at 1:09 PM
$ACTU is a software or technology company; must prove sustainable growth and competitive advantage.
0 · Reply
BioTuesdays
BioTuesdays Jan. 21 at 7:22 PM
$ACTU has announced plans to initiate a Phase 1/2 clinical program evaluating the oral tablet dosage form of elraglusib in patients with advanced cancer https://biotuesdays.com/2026/01/21/actuate-to-advance-elraglusib-tablet-to-phase-1-2-program-in-refractory-cancers/
0 · Reply
BillionerOfKing
BillionerOfKing Jan. 16 at 1:48 PM
$ACTU Current Stock Price: $5.31
0 · Reply
crimsonsunglo
crimsonsunglo Jan. 14 at 12:54 AM
$ACTU I really think this is a sleeper. Can someone I follow let me know if I’m missing something. Thanks!!
0 · Reply
crimsonsunglo
crimsonsunglo Jan. 13 at 3:40 PM
$XAIR, $UAVS, a sleeper you may want to watch is $ACTU
0 · Reply
crimsonsunglo
crimsonsunglo Jan. 12 at 2:07 PM
$ACTU
0 · Reply
Avocado_smash
Avocado_smash Jan. 12 at 1:57 PM
$ACTU
0 · Reply
crimsonsunglo
crimsonsunglo Jan. 12 at 1:57 PM
$ACTU might want to take a look. Great news out. FYI
1 · Reply
Avocado_smash
Avocado_smash Jan. 12 at 1:56 PM
$ACTU https://www.globenewswire.com/news-release/2026/01/12/3216938/0/en/Actuate-Therapeutics-Reports-Positive-Follow-Up-Data-from-its-Randomized-Controlled-Phase-2-Trial-Demonstrating-Extended-Long-Term-Overall-Survival-Benefit-with-Elraglusib-Plus-Che.html?_gl=1*1s3ds1o*_up*MQ..*_ga*MTgzMzczNTcwMC4xNzY4MjI2MTE4*_ga_ERWPGTJ5X8*czE3NjgyMjYxMTgkbzEkZzAkdDE3NjgyMjYxMTgkajYwJGwwJGgw
0 · Reply
Stock_Catcher
Stock_Catcher Jan. 12 at 1:45 PM
$ACTU Actuate Therapeutics Reports Positive Follow-Up Data from its Randomized Controlled Phase 2 Trial Demonstrating Extended Long-Term Overall Survival Benefit with Elraglusib Plus Chemotherapy for Metastatic Pancreatic Cancer in Oral Presentation at ASCO GI 2026
0 · Reply
_Jean123
_Jean123 Jan. 10 at 10:57 PM
🎯 $ACTU - THE NEXT BIOTECH MOONSHOT? 🚀 🔹 Analyst Target: $35.00 (Lucid Capital Markets) 🔹 Current Price: ~$6.14 (Upside +430%) 🔹 The Catalyst: ASCO GI 2026 data confirmed 43% reduction in death risk for Pancreatic Cancer. 🧬 🔹 Scarcity: Ultra Low Float (<5M effective). High Institutional interest. 💎 This isn't just a stock; it's a science-backed revolution. Monday gap-up loading... 📈 📑 Full Analyst Report ($35 PT): https://www.investing.com/news/analyst-ratings/actuate-therapeutics-stock-gets-buy-rating-after-positive-phase-1-results-93CH-4433361
0 · Reply
_Jean123
_Jean123 Jan. 9 at 6:44 PM
$ACTU THE DIP AT $6.00! 🚀🚀🚀 Don't let the market makers shake you out before the 1:30 PM poster release. 37% death risk reduction is a game-changer in this sector. $ACTU is literally a ticking time bomb with that tiny float. If the oral presentation tonight is a hit, $20 is the floor. HODL tight! 🔥📈 #ASCOGI2026 #ACTU
1 · Reply
Bulldog1776
Bulldog1776 Jan. 8 at 6:42 PM
$ACTU these oral presentations are great and all but I’ve seen in the past where the stock doesn’t really move much unless there is a PR or conference call. What do you all think about the upcoming presentations and stock price?
2 · Reply
G101SPM
G101SPM Jan. 7 at 8:17 PM
#SHOWTIME American Society of Clinical Oncology Gastrointestinal Cancers Symposium (January 8-10) Scheduled to appear: $ACTU, $CATX, $JAZZ, $ZYME
0 · Reply